GSA Capital Partners LLP Raises Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)

GSA Capital Partners LLP grew its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,127 shares of the company’s stock after acquiring an additional 403 shares during the quarter. GSA Capital Partners LLP’s holdings in MoonLake Immunotherapeutics were worth $1,116,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Avoro Capital Advisors LLC grew its holdings in shares of MoonLake Immunotherapeutics by 7.4% during the 2nd quarter. Avoro Capital Advisors LLC now owns 2,770,000 shares of the company’s stock valued at $121,797,000 after purchasing an additional 190,000 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of MoonLake Immunotherapeutics by 2.6% during the second quarter. Federated Hermes Inc. now owns 1,128,428 shares of the company’s stock valued at $49,617,000 after buying an additional 28,672 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the second quarter. Marshall Wace LLP now owns 1,098,630 shares of the company’s stock worth $48,307,000 after buying an additional 587,684 shares during the period. Westfield Capital Management Co. LP lifted its stake in shares of MoonLake Immunotherapeutics by 48.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 910,873 shares of the company’s stock valued at $45,753,000 after acquiring an additional 298,823 shares during the last quarter. Finally, Logos Global Management LP purchased a new stake in MoonLake Immunotherapeutics during the 2nd quarter valued at about $32,978,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock opened at $52.50 on Friday. MoonLake Immunotherapeutics has a fifty-two week low of $37.35 and a fifty-two week high of $64.98. The stock has a market cap of $3.35 billion, a price-to-earnings ratio of -40.70 and a beta of 1.28. The stock’s 50 day simple moving average is $49.68 and its two-hundred day simple moving average is $45.62.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the firm earned ($0.18) earnings per share. On average, analysts predict that MoonLake Immunotherapeutics will post -1.74 earnings per share for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, Director Simon Sturge sold 171,000 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $53.72, for a total value of $9,186,120.00. Following the sale, the director now owns 171,980 shares in the company, valued at approximately $9,238,765.60. This represents a 49.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.02% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, September 12th. Wedbush reaffirmed an “outperform” rating and issued a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Finally, Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a report on Monday, August 26th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.80.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.